Sana Biotechnology (SANA) EBITDA (2020 - 2026)

Sana Biotechnology's EBITDA history runs 7 years deep, the most recent figure standing at -$47.2 million for Q1 2026.

• In Q1 2026, EBITDA rose 4.38% year-over-year to -$47.2 million; the TTM figure through Mar 2026 stood at -$242.0 million (down 15.97% YoY), while the FY2025 annual figure was -$244.2 million, up 8.45% from the prior year.
• EBITDA came in at -$47.2 million for Q1 2026 at Sana Biotechnology, up from -$58.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.6 million in Q3 2023 to a low of -$112.7 million in Q2 2023.
• A 5-year average of -$65.3 million and a median of -$59.9 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA soared 101.93% in 2023 and slumped 3733.94% in 2024, its largest moves.
• Sana Biotechnology's EBITDA stood at -$78.4 million in 2022, then declined by 12.28% to -$88.0 million in 2023, then soared by 44.18% to -$49.1 million in 2024, then decreased by 19.77% to -$58.8 million in 2025, then grew by 19.68% to -$47.2 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$47.2 million, -$58.8 million, and -$42.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison